Full Text View
Tabular View
No Study Results Posted
Related Studies
Role of Metabolites in Nicotine Dependence (2) - 5
This study has been completed.
Study NCT00000288   Information provided by National Institute on Drug Abuse (NIDA)
First Received: September 20, 1999   Last Updated: November 3, 2005   History of Changes

September 20, 1999
November 3, 2005
December 1995
 
  • Subjective effects
  • Physiological effects
  • Behavioral
  • Subjective
Same as current
Complete list of historical versions of study NCT00000288 on ClinicalTrials.gov Archive Site
 
 
 
Role of Metabolites in Nicotine Dependence (2) - 5
Role of Metabolites in Nicotine Dependence (2)

The purpose of this study is to determine the effects of varying doses of cotinine on cigarette self-administration.

Previous studies have shown that cotinine, a metabolite of nicotine, antagonizes some of the effects of nicotine. One study showed that nicotine eliminates some of the beneficial effects of the nicotine patch in reducing withdrawal symptoms. The purpose of this study was to examine the effects of cotinine. The results generally showed no effects on self-administration of cigarettes, although higher serum nicotine levels were observed on the highest doses of cotinine compared to placebo or lower doses of cotinine.

Phase II
Interventional
Treatment, Double-Blind, Placebo Control, Crossover Assignment
Tobacco Use Disorder
Drug: Cotinine fumarate
 
 

*   Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
 
Completed
0
December 2002
 

Inclusion Criteria:

Male/Female subjects ages 21-45 yrs. inclusive, with a smoking history of at least 1 pack of cigarettes daily for at least 1 year. Subject must be in good health as verified by medical history, screening examination, and screening laboratory tests. Subject must provide written informed consent to participate in the study and be motivated to stop smoking for a short term.

Exclusion Criteria:

History of myocardial infarction, angina pectoris, sustained or episodic cardiac arrhythmias, symptomatic peripheral vascular disease, peptic ulcer disease or any other medical condition which the physician or investigator deems inappropriate for participation. Insulin-dependent diabetes. Pregnant or lactating, or not using adequate birth control methods. Requirement of any form of regular psychotropic medication (antidepressants, antipsychotics, or anxiolytics) and recent psychiatric history). Chronic use of systemic steroids or antihistamines. Skin sensitivity which would preclude use of a transdermal system. Abuse of alcohol or any other recreational or prescription drug. Use of any other tobacco products including smokeless tobacco and nicotine products. Previous use of transdermal nicotine system. Inability to fulfill all scheduled visits and examination procedures throughout the study period.

Both
21 Years to 45 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00000288
 
NIDA-09259-5, P50-09259-5
National Institute on Drug Abuse (NIDA)
University of Minnesota
Principal Investigator: Dorothy Hatsukami, Ph.D. University of Minnesota
National Institute on Drug Abuse (NIDA)
December 1996

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP